CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT ID: NCT05210283
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1017 participants
OBSERVATIONAL
2021-12-15
2027-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
NCT06398743
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
NCT06654622
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT07136077
Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
NCT04813627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage ll or lll
Patients with stage ll or lll colorectal cancer
MRD
ctDNA MRD test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRD
ctDNA MRD test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Post complete surgical resection of CRC, with last surgery occurring within 180 days prior to enrollment are eligible if all of the following conditions are met:
1. in the opinion of the surgeon, all grossly visible tumor was completely resected ("curative resection") and
2. histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells.
i. Patients with T4 tumors that have involved an adjacent structure (e.g., bladder, small intestine, ovary, etc.) by direct extension from the primary tumor must have had all or a portion of the adjacent structure removed en bloc with the primary tumor and local radiation therapy will not be utilized.
3. Pathologic stage II or III
4. ECOG performance status ≤ 2 (0, 1 or 2).
5. Able to understand and provide informed consent.
6. Willing and able to comply with the study requirements, which includes the collection of approximately 43mL of blood for each research blood draw.
Exclusion Criteria
2. Pregnant or breastfeeding at time of enrollment.
3. Prior history of any invasive cancer (including CRC) within the past 3 years prior to informed consent, with the exception of non-melanoma skin cancer. Patients with a prior history of noninvasive (in situ) carcinomas may participate after definitive treatment.
4. Prior transplant history:
1. Prior allogeneic hematopoietic stem cell transplant at any time.
2. Prior solid organ transplant within the last 2 years prior to enrollment.
5. Multiple cancer diagnoses: Synchronous or asynchronous diagnoses (or suspicion) of multiple primary cancers at the time of eligibility screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NSABP Foundation Inc
NETWORK
Exact Sciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology
Mission Hills, California, United States
Torrance Memorial Hunt Cancer Institute
Torrance, California, United States
University of Florida Division of Hematology & Oncology
Gainesville, Florida, United States
Mount Sinai Medical - Comprehensive Cancer Center
Miami Beach, Florida, United States
Mid Florida Cancer Centers
Orange City, Florida, United States
Edward Cancer Center
Elmhurst, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Mercy Medical Center
Cedar Rapids, Iowa, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital
Baltimore, Maryland, United States
Meritus Center for Clinical Research
Hagerstown, Maryland, United States
University of Maryland St. Joseph Medical Center
Towson, Maryland, United States
Metro Minnesota Community Oncology Consortium (MMCORC)
Saint Louis Park, Minnesota, United States
Missouri Baptist Medical Center
St Louis, Missouri, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Columbus NCORP
Columbus, Ohio, United States
Interstate Medical Office Central
Portland, Oregon, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Reading Hospital Hematology Oncology
West Reading, Pennsylvania, United States
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
WellSpan York Cancer Center
York, Pennsylvania, United States
Primsa Health Cancer Institute
Greenville, South Carolina, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
Ballad Health Cancer Center
Kingsport, Tennessee, United States
Marshfield Medical Center Weston
Weston, Wisconsin, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health - Glen Site
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.